GlobeNewswire by notified

Bulletin from the 2023 Annual General Meeting of Fingerprint Cards AB (publ)

Share

Fingerprint Cards AB (publ) held its Annual General Meeting today on May 24, 2023. A summary of the resolutions passed by the Meeting is set out below.

Dividend

The Meeting resolved that no dividend be paid.

Board of Directors and Auditors

The Meeting discharged the directors of the Board and the managing directors from liability in relation to the company for the period 1 January - 31 December 2022.

The Meeting re-elected Christian Lagerling, Alexander Kotsinas, Dimitrij Titov and Juan Vallejo and elected Mario Shiliashki and Adam Philpott as Board Members. Christian Lagerling was re-elected as Chairman of the Board of Directors.

The Meeting resolved that Board remuneration shall be SEK 675,000 to the Chairman of the Board and SEK 295,000 to each other Member of the Board. Remuneration to the Chairman of the Audit Committee shall be SEK 135,000 and SEK 70,000 to each other member. Remuneration to the Chairman of the Remuneration Committee shall be SEK 85,000 and SEK 45,000 to each other member.

The Meeting resolved to re-elect BDO Mälardalen AB, with Authorized Public Accountant Johan Pharmanson as Auditor-in-Charge, and Authorized Public Accountant Carl-Johan Kjellman, BDO Mälardalen AB, as auditors up until the end of the next Annual General Meeting.

The Meeting resolved that remuneration of auditors shall be paid in accordance with approved invoices.

Remuneration report

The Meeting resolved to approve the Board of Directors’ report over remuneration regarding 2022 according to Chapter 8, Section 53 a of the Swedish Companies Act.

Authorization of the Board to decide on the repurchase and transfer of class B treasury shares

The Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board to repurchase, on one or several occasions up until the next Annual General Meeting, as many class B shares in the company as may be purchased without the company's holding at any time exceeding ten (10) per cent of the total number of outstanding shares in the company. The Board of Directors was also authorized to resolve, on one or several occasions up until the next Annual General Meeting, to transfer the company's class B shares, with deviation from the shareholders' preferential rights.

Authorization of the Board to resolve on the issue of new shares with or without preferential rights for the shareholders

The Meeting resolved to authorize the Board of Directors to resolve, on one or several occasions up until the next Annual General Meeting, with or without deviation from the shareholders' preferential rights, on new issues of class B shares, warrants and/or convertibles entitling to subscription of class B shares corresponding to no more than twenty (20) percent of the total number of outstanding shares in the company.

For further information, please contact:

Investor Relations:

+46(0)10-172 00 10

investrel@fingerprints.com

Press:

+46(0)10-172 00 20

press@fingerprints.com

About Fingerprints
Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden.
We believe in a secure and seamless universe, where you are the key to everything. Our solutions are found in hundreds of millions of devices and applications, and are used billions of times every day, providing safe and convenient identification and authentication with a human touch. For more information visit our website, read our blog, and follow us on Twitter. Fingerprints is listed on Nasdaq Stockholm (FING B).

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye